Atlas Trials

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

Clinical trial NCT03993964 · UNKNOWN

Trial details

NCT number
NCT03993964
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2019-08-15
Primary completion
2020-10-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.